Perfect Medical Health Management (1830) H1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2027 earnings summary
16 Nov, 2026Executive summary
Revenue was broadly stable at HK$482.9m, down 0.6% YoY, while attributable profit rose 52.9% to HK$145.0m as network rightsizing and cost controls improved operating leverage.
The leaner operating platform, debt-free balance sheet and strong operating cash generation support management’s confidence in sustainable long-term value creation.
Financial highlights
Operating profit increased 59.6% to HK$177.2m; EBITDA, defined as operating profit plus PPE depreciation, rose 38.9% to HK$197.6m.
Profit before tax rose 58.6% to HK$175.2m; profit for the period increased 59.6% to HK$144.9m.
Attributable profit increased 52.9% to HK$145.0m; basic and diluted EPS rose to HK11.5 cents from HK7.5 cents.
Aggregate key costs fell 18.7% to HK$311.1m, including employee expenses down 11.7%, marketing down 16.6% and other operating expenses down 24.8%.
Outlook and guidance
Priorities include productivity gains across the optimized Hong Kong network, deeper membership engagement and AI-enabled marketing, cross-selling, and further development of medical beauty and wellness services.
Management plans to build on Macau’s momentum and the Australia and Singapore turnarounds, while protecting Mainland China margins and pursuing measured, high-return opportunities as conditions allow.
Disciplined cost management, capital allocation and sustainable shareholder returns remain central; no quantified financial guidance was stated.
Latest events from Perfect Medical Health Management
- Profitability rebounded in H2, margins improved, and a 100%+ dividend payout was maintained.1830
H2 2026 - Profit rebounded 43.4% sequentially on cost discipline, with a 101.3% dividend payout ratio.1830
H1 2026 - Revenue and profit declined sharply, but high margins and strong dividends were maintained.1830
H2 2025 - Revenue and profit declined, but cost control and full dividend payout support ongoing expansion.1830
H1 2025 - Revenue and profit rose modestly, with strong dividends and strategic expansion in key markets.1830
H2 2024